Evaluation of Urinary Ceruloplasmin as a Novel Biomarker for Lupus Nephritis

Background: A crucial step in modifying the course of lupus nephritis is early identification kidney disease systemic patients. Lupus affects around 30% to 60% SLE patients and 70% juvenile SLE. Renal biopsy, which an invasive procedure with hazards, considered gold standard diagnose Nephritis. Ceruloplasmin (CP) acute phase protein that transports most circulating copper functions as iron oxidase associated metabolism, has been found urinary exosomal increased diseases due local tissue pro-inflammatory cytokines such TNF-a, IL-6, IL-1a. this study aimed evaluate utility ceruloplasmin a new biomarker differentiate from non-nephritis, correlation activity. Patients Methods: Case control included sixty thirty controls. The case group subdivided into 30 (LN) & Non-nephritis (NN) following were measured: CBC, ESR urine analysis, Ceruloplasmin, serum creatinine, 24-hr urine, eGFR (MDRD Equation), C3&C4, Anti-dsDNA, ANA. Results: Elevated levels higher than controls by further stratification; be greater non-nephritis group, also, have significant positive activity, duration, negative eGFR, C3&C4 Conclusion: Urinary potentiality non-nephritis.